| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
Batatasin IV targets leukotriene A4 hydrolase (LTA4H), an enzyme involved in the biosynthesis of leukotriene B4 (LTB4), a pro-inflammatory mediator. By inhibiting LTA4H, Batatasin IV reduces the production of LTB4 and exerts anti-inflammatory effects. It also exhibits anti-cancer activity through mechanisms that may involve apoptosis induction.
|
|---|---|
| ln Vitro |
In vitro, Batatasin IV inhibits LTA4H activity and exhibits anti-inflammatory activity. It also shows potential anti-cancer properties by inhibiting tumor growth and inducing apoptosis in cancer cells. Specific IC50 values for LTA4H inhibition are not provided in the available sources.
|
| ln Vivo |
In vivo activity data for Batatasin IV are not extensively detailed in the available sources. As a natural product with anti-inflammatory and anti-cancer properties, it has potential for therapeutic applications, but specific in vivo studies are not described.
|
| Enzyme Assay |
The in vitro enzyme assay for Batatasin IV involves measuring the inhibition of LTA4H activity. Recombinant LTA4H is incubated with its substrate (leukotriene A4) in the presence of varying compound concentrations. The inhibition of LTB4 production is quantified using techniques such as ELISA or HPLC.
|
| Cell Assay |
Cellular assays for Batatasin IV are not specifically described in the available sources. The compound's anti-inflammatory activity can be assessed in cell-based systems by measuring LTB4 production or by evaluating its effects on inflammatory cytokine expression.
|
| Animal Protocol |
In vivo animal studies for Batatasin IV are not detailed in the available sources. The compound is a natural product being investigated for its potential therapeutic applications, but specific animal models and dosing regimens are not described.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Batatasin IV are not available in the provided sources. As a natural product, its absorption, distribution, metabolism, and excretion properties are not well characterized.
|
| Toxicity/Toxicokinetics |
Toxicity data for Batatasin IV are not reported in the available sources. As a naturally occurring compound found in food, it is generally considered to have a favorable safety profile, but specific toxicological studies are not described.
|
| References | |
| Additional Infomation |
Batatasin IV is a stilbene compound. Batatasin IV has been reported in yam, winged yam, and other organisms for which data are available.
Batatasin IV is a natural product with potential anti-inflammatory and anti-cancer activities. It is being investigated for its therapeutic potential in inflammation and cancer. The compound is available from chemical suppliers for research use only. |
| Molecular Formula |
C15H16O3
|
|---|---|
| Molecular Weight |
244.2857
|
| Exact Mass |
244.11
|
| CAS # |
60347-67-3
|
| PubChem CID |
181271
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.198g/cm3
|
| Boiling Point |
416.5ºC at 760 mmHg
|
| Melting Point |
99.5 - 100.5 °C
|
| Flash Point |
205.7ºC
|
| Index of Refraction |
1.61
|
| LogP |
2.891
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
18
|
| Complexity |
244
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C([H])([H])[H])C1C([H])=C(C([H])=C(C=1[H])C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1O[H])O[H]
|
| InChi Key |
IUMFLNFLJUUODE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H16O3/c1-18-14-9-11(8-13(16)10-14)6-7-12-4-2-3-5-15(12)17/h2-5,8-10,16-17H,6-7H2,1H3
|
| Chemical Name |
3-[2-(2-hydroxyphenyl)ethyl]-5-methoxyphenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0935 mL | 20.4675 mL | 40.9350 mL | |
| 5 mM | 0.8187 mL | 4.0935 mL | 8.1870 mL | |
| 10 mM | 0.4093 mL | 2.0467 mL | 4.0935 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
